Skip to content

Intensity modulated radiotherapy with IGRT for Post cricoid and upper esophageal cancer: Prospective observational study

Intensity modulated radiotherapy with IGRT for Post cricoid and upper esophageal cancer: Prospective observational study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/11/010428
Enrollment
40
Registered
2017-11-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Biopsy proven Squamous Cell Carcinoma of Post- cricoid and Upper cervical esophagus

Interventions

None listed

Sponsors

Varian Medical Systems Inc
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Biopsy-proven squamous cell carcinoma of the post cricoid and upper esophagus, with AJCC 7th edition stage T1-3N0-1,2M0 2.Lesions of the cervical and upper thoracic esophagus but not involving the mid and lower third of thoracic esophagus 3.Suitable for radical treatment with RT alone or Concurrent Chemo-radiotherapy 4.No significant co-morbidities that would interfere with treatment 5.Reliable for follow-up and signed informed consent. 6.Karnofsky performance status (KPS) between 70 and 100

Exclusion criteria

Exclusion criteria: 1.Age less than 18; 2.Previous treatment (e.g. chemotherapy, radiation therapy, laser therapy or surgery) for esophageal or head and neck cancer (gastrostomy or PEG does not constitute exclusion criteria); 3.Previous thoracic radiation therapy for any cause; 4.Evidence of other uncontrolled malignancies; 5.Severe compromised pulmonary function due to pulmonary disease eg. COPD 6.Scoliosis/kyphosis; 7.Failure to complete all baseline assessments required for the study. 8.Dysfunctional larynx (gross exolaryngeal extension, need for tracheostomy)

Design outcomes

Primary

MeasureTime frame
Event free survivalTimepoint: Event free survival

Secondary

MeasureTime frame
Acute and Late toxicity Quality of lifeTimepoint: At any time

Countries

India

Contacts

Public ContactDr Sarbani Ghosh Laskar

Tata Memorial Hospital

sarbanilaskar@gmail.com9820834386

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026